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Abstract
Aims Disrupted intermediary metabolismmay contribute to the
adverse pregnancy outcomes in women with very severe obe-
sity. Our aim was to study metabolism in such pregnancies.
Methods We recruited a longitudinal cohort of very severely
obese (n=190) and lean (n=118) glucose-tolerant women for
anthropometric and metabolic measurements at early, mid and
late gestation and postpartum. In case–control studies of very
severely obese and lean womenwemeasured glucose and glyc-
erol turnover during low- and high-dose hyperinsulinaemic–
euglycaemic clamps (HEC) at early and late pregnancy and in
non-pregnant women (each n=6–9) and body fat distribution
by MRI in late pregnancy (n=10/group).
Results Although greater glucose, insulin, NEFA and insulin
resistance (HOMA-IR), and greater weight and % fat mass
(FM) was observed in very severely obese vs lean participants,
the degree of worsening was attenuated in the very severely
obese individuals with advancing gestation, with no difference
in triacylglycerol (TG) concentrations between very severely
obese and lean women at term. Enhanced glycerol production
was observed in early pregnancy only in very severely obese
individuals, with similar intrahepatic FM in very severely obese
vs lean women by late gestation. Offspring from obese mothers
were heavier (p=0.04).
Conclusions/interpretation Pregnancies complicated by obe-
sity demonstrate attenuation in weight gain and insulin resis-
tance compared with pregnancies in lean women. Increased
glycerol production is confined to obese women in early preg-
nancy and obese and lean individuals have similar intrahepatic
FM by term. When targeting maternal metabolism to treat
adverse pregnancy outcomes, therapeutic intervention may
be most effective applied early in pregnancy.
Keywords Insulin resistance .MRI . Pregnancy . Stable
isotope studies . Very severe obesity
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Introduction
The prevalence of obesity is increasing in women of
childbearing age [1, 2]. In the UK 20% of pregnant
women are obese and 2% have very severe obesity
(BMI ≥40 kg/m2) [3]. The adverse maternal conse-
quences of obesity in pregnancy include Caesarean sec-
tion, haemorrhage and infection [4–6] along with still-
birth and neonatal intensive care unit admission [7].
Children born to obese mothers are more likely to be
large for gestational age (LGA) (and small for gestation-
al age [SGA]) and have a greater lifetime risk of obe-
sity [8–10], with health [11] and economic implications
[12].
The mechanism by which maternal obesity causes
harm to mother and child is unclear, and disrupted inter-
mediary metabolism may play a major role [13]. In the
non-pregnant state, obese individuals are insulin resistant
with high circulating levels of metabolites and inflamma-
tory markers, and a predisposition to hyperglycaemia [14,
15]. Pregnancy is an insulin-resistant state and the conse-
quent mobilisation of fatty acids and glucose provide sub-
strates for fetal growth [16–20]. Although mothers with a
diagnosis of gestational diabetes mellitus (GDM) are more
likely to have LGA infants [21, 22], maternal glucose
concentrations within the normal range are associated
with neonatal adiposity [21]. Studies comparing metabo-
lism in obese and lean pregnant women have yielded in-
conclusive results for insulin sensitivity [20, 23, 24],
which likely reflect small sample sizes, differences in
study design [20] and confounding by co-existing disease
[24].
The metabolic response to pregnancy evolves through-
out gestation [16, 17], and longitudinal measurements are
impor t an t . No p rev ious s t ud i e s have used the
hyperinsulinaemic–euglycaemic clamp (HEC), to compare
insulin sensitivity of glucose and lipid metabolism in such
pregnant women. We aimed to compare metabolic re-
sponses to pregnancy in lean and very severely obese wom-
en using a large prospective longitudinal cohort, sampled at
three time points in pregnancy and four months’ postpar-
tum, to investigate differences in adiposity, glucose and
lipid metabolism. At delivery, birthweights and complica-
tions were recorded.
Case–control studies were undertaken including: (1)
in-depth metabolic assessments of insulin resistance at
key time points, including whole-body glucose disposal,
endogenous glucose production (EGP) and glycerol
turnover using stable isotope methodology; (2) quantifi-
cation of fat mass (FM) by MRI and magnetic reso-
nance spectroscopy (MRS).
We aimed to examine women with normal glucose toler-
ance, to exclude the confounding effect of GDM.
Methods
Part I: longitudinal cohort study
Participants Participants were enrolled from May 2008
until May 2012 (Electronic Supplementary Material
[ESM] Fig. 1). We recruited very severely obese women
(booking BMI ≥40 kg/m2) from our antenatal clinic and
lean (BMI ≥20<25 kg/m2) controls via referrals from the
community to our clinic. Personal information (parity,
ethnicity, smoking status, and social and demographic da-
ta) was collected [25]. The main exclusions were pre-
existing diabetes, miscarriage prior to first assessment
and major anomalies. Women who developed GDM
(International Association of Diabetes in Pregnancy
Study Guidelines [IADPSG] criteria) [26], or did not un-
dergo an OGTT at 24–28 weeks’ gestation, or developed
pre-eclampsia [27] or delivered <37 weeks’ gestation
were excluded from analyses (ESM Fig. 1). Postnatal data
were included regardless of breastfeeding status, hormon-
al contraception or stage of menstrual cycle.
Timing of assessmentsWe aimed to assess early (~16 weeks),
mid (~28 weeks) and late (~36 weeks) gestation and postpar-
tum (~4 months postpartum). Gestational age was calculated
from the first day of the mother’s last menstrual period, or, from
the dating scan. Actual gestational and post-delivery ages, me-
dian (interquartile range [IQR]), were early: 17.8 (16.1–19.4)
weeks, mid: 28.1 (27.4–28.5) weeks and late: 36.1 (35.7–36.7)
weeks, and 18.0 (15.0–22.5) weeks postpartum.
Anthropometric measurements Women were weighed
(SECA chair scales model 959, Birmingham, UK), their
heights recorded, body fat estimated by bio-electrical imped-
ance (Tanita Scales BC 420 MA, Amsterdam, the
Netherlands) and BP recorded (Trimline Medical Products,
Branchburg, NJ, USA).
Blood samplingVenous blood samples at the above time points
were collected after an overnight fast. A 2 h 75 g OGTT was
performed between 24 and 28 weeks’ gestation and samples
stored at −80°C for later determination of metabolites.
Laboratory analyses Glucose concentrations were mea-
sured by a hexokinase method (Randox Laboratories, Co.
Antrim, UK). NEFA, total cholesterol, HDL-cholesterol,
triacylglycerol (TG) and liver function tests (LFTs) were
measured by colorimetric methods (NEFA: Wako
Chemicals, Neuss, Germany; total cholesterol: Olympus
Diagnostics, Watford, UK; TG: Alpha Laboratories,
Eastleigh, UK; LFTs: Abbott Diagnostics, Maidenhead,
UK). Serum samples for insulin and C-peptide were
analysed by ELISA (Mercodia, Uppsala, Sweden).
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Assessment of insulin secretion and insulin resistance
HOMA was used to compute insulin secretion (HOMA%B)
and insulin resistance (HOMA-IR) [28].
Obstetric outcome Birthweight (SECA 384 scales,
Birmingham, UK), sex and gestational age at delivery were
recorded. An LGA infant was defined as a sex-specific
birthweight for gestational age >90th percentile and an SGA
infant <10th percentile [29]. Adverse obstetric outcomes re-
corded were the rate of Caesarean section, perineal tears and
episiotomies during spontaneous vaginal deliveries, neonatal
complications, maternal haemorrhage and admissions to the
high dependency unit (HDU).
Part II: case–control studies
Participants In the longitudinal study, initial data revealed a
decrease in circulating glucose in lean women only from early
to late pregnancy (Fig. 1). To explore this, further groups of
women were recruited in nested case–control studies, includ-
ing: (1) lean and very severely obese pregnant and non-
pregnant women, who underwent HEC studies with stable
isotope tracer infusions at early (~19 weeks) or late
(~36 weeks) gestation or when not pregnant; and (2) groups
of lean and obese pregnant women who underwent MRI/MRS
analysis of subcutaneous, visceral, intramuscular and
intrahepatic fat at late gestation (Table 1). Exclusions were
as in the longitudinal cohort study.
Anthropometric and laboratory analyses were performed as
previously described.
HEC and tracer studies Participants (n=6–9/group at
19 weeks’ gestation) attended the Research Facility at
08:00 hours after an overnight fast [30]. Participants received
infusions of [2H2]glucose and [
2H5]glycerol (Cambridge
Isotope Laboratories, Andover, MA, USA; prime 25 μmol/kg,
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Fig. 1 Weight andmetabolic data
of NGT obese and lean control
participants. Data at early
(~16 weeks [w]) (n=190, obese
[white bars], n=118 lean [black
bars]), mid (~28 weeks) and late
(~36 weeks) gestation and
postpartum. (a) Weight, (b)
glucose, (c) NEFA, (d) TG, (e)
insulin and (f) HOMA-IR.
Median±IQR demonstrated at
each visit. Repeated ANOVA
analyses were performed from the
three visits during pregnancy and
again on the four visits including
the postpartum (PP) visit.
*p<0.05, **p<0.01, ***p<0.001
Diabetologia
continuous infusion 0.22 μmol kg−1 h−1 and prime
1.6 μmol/kg, continuous infusion 6.6 μmol kg−1 h−1,
respectively) for 4.5 h. Blood samples were taken at
10 min intervals at the end of three 90 min periods with
infusion of: (1) no insulin; (2) insulin (Actrapid,
NovoNordisk, Bagsvaerd, Denmark.) 20 mU m−2 min−1
(suppresses l ipolysis and EGP); and (3) insulin
40 mU m−2 min−1 (stimulates glucose uptake). Glucose
was maintained at 5 mmol/l with 20% dextrose. Blood
samples were centrifuged and plasma stored at −80°C.
The quantity of glucose infused during the final 30 min
of the high-dose HEC divided by the insulin concentra-
tions was the insulin-stimulated glucose disposal index
(M/I value) [31].
The rate of appearance and disappearance (Ra/Rd) of the
tracee was calculated [31]:
Ra ¼ Rd ¼ F=TTR plasma tracer– Fð Þ
where F is the infusion rate of tracer and TTR is the
tracer:tracee ratio.
Mass spectrometry analyses Standard curves were pre-
pared [15] and glycerol triacetate m/z 217, [2H5]glycerol
triacetate m/z 222, butanetriol triacetate m/z 231 (internal
standard), glucose pentaacetate m/z 287, [2H2]glucose
pentaacetate m/z 289 and [13C6]glucose pentaacetate m/z
293 (internal standard) monitored.
Table 1 Anthropometric and personal data of participants in all study groups
Variable Case–control metabolic study Case–control MRI/MRS
study
p values for one-wayANOVA
of four study groups
Pregnant
lean
Pregnant
obese
Non-pregnant
lean
Non-pregnant
obese
Pregnant
lean
Pregnant
obese
Lean Obese
n 6 9 7 7 10 10
Gestation at
recruitment (days)
133
(130–140)
133
(129–139)
N/A N/A 258
(254–261)
256
(252–258)
Age (years) 35±0.7a,b 27±1.2*** 25.9±0.7 34.4±1.9 32.5±1.2 28.4±1.1* <0.0001 0.02
BMI (kg/m2) 24.2
(22.6–24.5)
41.2***
(38.8–44.8)
22.2
(21.3–23.7)
41.8
(36.6–45.2)
26.3
(24.9–28.8)
45.6***
(42.9–49.1)
0.46 0.33
Weight (kg) 63.6
(60.3–67.1)
115.6***
(113.0–124.0)
60.4
(57.9–65.6)
111.4
(96.4–116.8)
74.2
(65.8–81.2)
118.7***
(112.1–135.7)
0.84 0.48
Height (m) 1.65
(1.60–1.67)
1.68
(1.60–1.72)
1.66
(1.63–1.67)
1.63
(1.59–1.68)
1.67
(1.60–1.69)
1.64
(1.60–1.66)
0.18 0.54
Waist (cm) 85a
(80–98)
116***
(113–119)
74
(71–76)
115
(112–124)
N/A N/A 0.003 0.99
Parity (0/1/>2; %) 17/83/0a 45/55/0 100/0/0c 20/40/60 60/30/10 30/40/30 0.005 0.40
Ethnicity (n[%]white) 6
(100)
9
(100)
7
(100)
7
(100)
10
(100)
10
(100)
0.81 0.67
Current smoker (%) 0 0 0 14 0 0 0.90 0.51
Social class (DEPCAT code) 2±0 4±0** 3±1 4±1 3±0 4±0* 0.14 0.95
Data are means±SEM or median (IQR)
One-way ANOVA analyses were performed separately in lean control participants and obese participants from the four study groups (waist circumfer-
ence in three study groups), which included (1) the longitudinal study (data not shown above—anthropometry demonstrated in Table 2); ethnicity 96%
white in lean and obese groups; current smokers: 2% vs 11%** and DEPCATcode 3±1 vs 4±1*** in lean and obese groups; (2) the case–control study
with pregnant participants and (3) case–control study with non-pregnant participants, and (4) MRI study with pregnant participants studied in late
gestation only. Post hoc testing was carried out between the obese and lean control participants within the study groups and differences denoted:
*p<0.05; **p<0.01; ***p<0.001
Post hoc testing was done between the obese participants in all the studies and the lean control participants in all the studies:
a Pregnant case–control study vs non-pregnant
b Pregnant case–control metabolic study vs pregnant case–control MRI study
cNon-pregnant vs pregnant case–control MRI study
There were no statistical differences between the following groups:
Pregnant longitudinal study vs pregnant case–control metabolic study
Pregnant longitudinal study vs non-pregnant
Pregnant longitudinal study vs pregnant case–control MRI study
DEPCAT code, deprivation category score (greater score indicates greater economic deprivation)
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MRI Whole-body MRI and proton MRS (1H-MRS) studies
were performed on a 3T MAGNETOM Verio MRI system
(Siemens AG Healthcare Sector, Erlangen, Germany).
Women attended after an overnight fast, were positioned in
the magnet on their left lateral side, and data from abdomen,
liver, quadriceps and paraspinal tissue was acquired using a
combination of spine and body matrix coil elements.
For 1H-MRS measurement of intramyocellular lipid
(IMCL), single voxel (2 cm3) spectra localised to the right
quadriceps muscle were acquired using a PRESS sequence
(TR 5,000 ms/TE 30 ms) [32]. The hepatic fat fraction was
derived using the Dixon method [14, 33]. Abdominal volume
was estimated from 20×2 mm slices above the left renal
pelvis.
To derive FM, adipose tissue volumes were analysed in
triplicate using SliceOmatic v4 (TomOvision, Magog, QC,
Canada). 1H-MRS analyses used the AMARES algorithm in
jMRUI software version 3 (www.jmrui.eu/) [34, 35].
Sample size calculations and statistical analyses Statistical
analyses were performed (Stata 12, Stata Corporation, TX,
USA). Data are presented as the mean±SEM, or median
(IQR) as appropriate. Categorical variables were compared
using the χ2 or Fisher exact test. In the longitudinal cohort,
the independent effects of lean vs very severely obese status
and gestational age and their interaction were analysed using
two-way repeated ANOVA. Post hoc analyses determined dif-
ferences between lean vs very severely obese groups and dif-
ferences between time points in the obese and then separately
in the lean groups. Birthweight percentiles were adjusted for
maternal age, socioeconomic status, smoking status and eth-
nicity in multiple logistic regression models to further explore
differences between the groups. Logistic regression analyses
were performed to determine if there was a metabolic indica-
tor independent of obesity, associated with adverse obstetric
outcomes.
In case–control metabolic studies, the independent effects
of lean vs obese and gestational age/non-pregnant status and
their interaction were analysed similarly with post hoc analy-
ses (lean vs obese then gestational age/non-pregnant status in
each group). For tracer studies two-way ANOVA analyses at
basal state, low and high-dose insulin infusion were per-
formed. MRI studies were compared by unpaired t tests or
Mann–Whitney tests. A p value <0.05 indicated statistical
significance.
We aimed to generate data for >200 obese and 100 lean
women for the longitudinal study; formal sample size calcu-
lations were not performed. For the case–control study we
calculated that the sample size used would have 80% power
at the 5% significance level to show a difference betweenM/I
values in obese and lean women that might be maintained by
the end of pregnancy. Themedian (IQR)M/I value at termwas
0.19 (0.11–0.26) in lean and 0.10 (0.08–0.21) in the obese
groups. Therefore n=30 per group would give 80% power
to show these differences were significant at the 5% signifi-
cance level.
Ethics approval Participants provided written informed con-
sent and the study was approved by institutional review
boards (Lothian Research Ethics Committee, UK; reference
08/S1101/39) in accordance with principles endorsed by the
Declaration of Helsinki.
Results
Part I: longitudinal cohort study
ParticipantsWomen with very severe obesity (411) and lean
women (138) at ~16 weeks’ gestation were assessed and fol-
lowing exclusions, data on 190 very severely obese and 118
lean control women were analysed (ESM Fig. 1). Postpartum
declines and 3 month postnatal milestone not reached by ter-
mination of the study, explained lower numbers at this stage.
Personal and anthropometric data are shown (Tables 1 and 2).
Pregnant women in very severely obese groups were younger
and more socioeconomically deprived than all lean pregnant
groups (p<0.05).
Anthropometric and metabolic indices Body weight and
FM were greater in the very severely obese women and in-
creased during pregnancy in both groups, although absolute
weight gainwas greater in lean controls at ~28 and ~36weeks’
gestation (Fig. 1; Table 2). Percentage body fat increased dur-
ing pregnancy in lean women only (Table 2). Systolic and
diastolic BPs were greater in very severely obese compared
with lean women (Table 2) and increased with advancing ges-
tation in both groups.
Fasting glucose and insulin concentrations were higher in
the very severely obese compared with the lean women at all
visits (Fig. 1; Table 3). In both groups, glucose was lower and
insulin concentrations higher during pregnancy than postpar-
tum, with a progressive rise in insulin concentrations between
16 and 36 weeks of pregnancy. There were no differences in
2 h glucose concentrations at 24–28 weeks’ gestation
(Table 3). HOMA%B and HOMA-IR were greater in very
severely obese compared with lean women at all stages of
pregnancy (Fig. 1; Table 3). However, in contrast to lean
women, who displayed increasing HOMA-IR through preg-
nancy with a decrease postpartum, in the obese group there
was no difference between mid and late gestation HOMA-IR
or between postpartum and early pregnancy HOMA-IR.
Similarly, TG, NEFA, total and LDL-cholesterol were greater
at late compared with early gestation in each of obese and lean
groups, with no difference in TG concentrations in obese com-
pared with lean groups by late gestation (Table 3).
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The majority of metabolic variables changed with advanc-
ing gestation except fasting plasma glucose and alanine trans-
aminase (ALT; Table 3). The liver-specific enzyme
γ-glutamyl transferase (GGT), which may be increased with
the presence of fat in the liver, decreased in all mothers
through pregnancy but this decrease started in mid-
pregnancy in the obese and later in the lean mothers.
Obstetric outcomes Birthweights from very severely
obese vs lean mothers were greater: 3,636±37 vs 3,
556±43 g (p=0.04) with, after adjusting for maternal
factors, an increased prevalence of LGA infants: 41%
vs 31%, respectively (p=0.04; ESM Table 1) but no
difference in prevalence of SGA infants. Preterm births
in the obese group were greater (ESM Fig. 1). In the
lean vs very severely obese women, the Caesarean sec-
tion rate was 19% vs 42% (p<0.001); 55% and 46%
were emergency sections in the groups, respectively
(p=0.06). In those delivering by spontaneous vaginal
delivery, instrumentation was necessary in 46% vs
41% and perineal tears/episiotomy was observed/
performed in 78% vs 76% of lean vs very severely
obese mothers (both p>0.05). Postpartum haemorrhage
was 1% vs 5%, maternal HDU admissions 5% vs 12.5%
and neonatal HDU admissions 5% vs 4% in lean vs
very severely obese mothers, respectively (all p>0.05).
Fasting glucose concentrations in the third trimester was
the only metabolite significantly associated with any ad-
verse obstetric outcome but there were no metabolic
associations with Caesarean section alone.
Table 2 Anthropometry and BP in longitudinal cohort study participants at early, mid and late gestation, and postpartum
Variable Early gestation
(~16 weeks)
Mid gestation
(~28 weeks)
Late gestation
(~36 weeks)
Postpartum
(~3–6 months)
Lean Obese Lean Obese Lean Obese Lean Obese
n 118 190 117 184 115 178 92 95
Gestation (days) 117
(106–126)
132***
(119–145)
199
(197–201)
194***
(191–199)
255
(253–257)
252***
(249–256)
122
(109–147)
130
(109–175)
BMI (kg/m2) 22.7
(21.4–23.8)
42.7***
(40.8–44.8)
25.0a
(23.8–26.3)
44.0***a
(42.1–46.4)
26.2b,c
(24.8–27.9)
45.0***b,c
(43.0–47.5)
22.5d,e
(21.3–24.1)
42.9***d,e
(40.3–46.0)
Weight (kg) 63.2
(57.7–67.3)
115.0***
(108.9–122.1)
70.0a
(64.4–74.2)
118.5***a
(112.3–124.4)
80.0b,c
(67.6–77.7)
121.0***b,c
(114.4–127.8)
61.4d,e
(58.3–67.6)
112.7***d,e
(106.6–122.2)
Body fat (%) 28.7
(25.7–32.7)
48.8***
(47.2–51.3)
32.5a
(29.1–35.7)
49.5***
(47.0–51.2)
34.7b,c
(30.3–37.4)
48.9***
(46.6–51.3)
28.9d,e
(24.8–33.1)
49.5***
(47.1–51.2)
Weight change (from 16 weeks) 6.2
(4.6–7.8)
2.9***
(0.7–5.3)
9.5c
(7.6–12.0)
5.4***
(2.9–9.4)
−0.7d,e
(−3.1–2.6)
0.3
(−4.4–3.5)
SBP (mmHg) 105
(100–110)
118***
(110–124)
108
(100–113)
118***
(110–120)
110b,c
(104–118)
120***b,c
(110–130)
108e
(100–112)
120***e
(110–125)
DBP (mmHg) 60
(60–67)
70***
(65–75)
60
(60–68)
70***
(66–74)
65b,c
(60–70)
72***b,c
(70–80)
65
(60–70)
70***d,ef
(68–80)
Data presented as median (IQR)
The independent effects of lean control vs obese status and gestational age, and their interaction, were examined using two-way repeated measures
ANOVA on the variables in early, mid and late gestation in all the pregnant mothers and again in early, mid and late gestation and postpartum in the
mothers attending the postpartum visit. All two-way repeated measures ANOVA analyses during pregnancy (n=111 lean, n=150 obese) and then
analyses for all women attending postpartum (n=85 lean, n=85 obese) revealed significant differences in lean vs obese status, gestational age and
significant interactions between these two variables (all p≤0.01). The exception was the interaction for SBP and DBP in pregnancy and for the
pregnancy+postpartum visit (both p>0.05) (data not displayed)
Post hoc analyses for differences between lean controls vs obese at each time point were performed and differences denoted:
***p<0.001
Post hoc analyses for differences between time points were done separately in the controls and obese and are denoted:
aMid vs early gestation
b Late vs early gestation
c Late vs mid gestation
d Postpartum vs mid gestation
e Postpartum vs late gestation
f Postpartum vs early gestation
DBP, diastolic BP; SBP, systolic BP
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Table 3 Metabolic data of longitudinal cohort study participants at early, mid and late gestation, and postpartum
Variable Early gestation
(~16 weeks)
Mid gestation
(~28 weeks)
Late gestation
(~36 weeks)
Postpartum
(~3–6 months)
Lean Obese Lean Obese Lean Obese Lean Obese
n 118 190 117 184 115 178 92 95
Gestation (days) 117
(106–126)
132*
(119–145)
199
(197–201)
194*
(191–199)
255
(253–257)
252*
(249–256)
122
(109–147)
130
(109–175)
Fasting plasma glucose (mmol/l) 4.2
(4.0–4.4)
4.4*
(4.2–4.6)
4.2
(4.0–4.5)
4.4*
(4.2–4.7)
4.1
(3.9–4.3)
4.4*a
(4.1–4.6)
4.4b,c,d
(4.1–4.7)
4.8*b,c,d
(4.5–5.0)
2 h glucose (mmol/l) 4.9
(4.2–5.7)
5.3
(4.7–6.0)
NEFA (mmol/l) 0.33
(0.25–0.42)
0.49*
(0.42–0.59)
0.33
(0.24–0.44)
0.45*e
(0.38–0.55)
0.40a,f
(0.30–0.55)
0.52*
(0.41–0.64)
0.46b,c,d
(0.37–0.65)
0.46
(0.36–0.63)
Total cholesterol (mmol/l) 4.9
(4.6–5.8)
5.2
(4.5–6.0)
6.4e
(5.4–7.4)
5.7*e
(5.0–6.8)
6.9a,f
(6.0–7.9)
6.1*f
(5.1–7.2)
5.1c,d
(4.6–6.1)
4.8*b,c,d
(4.0–5.4)
HDL-cholesterol (mmol/l) 1.9
(1.7–2.3)
1.5*
(1.3–1.8)
1.9
(1.7–2.2)
1.6*
(1.4–1.9)
1.8f
(1.5–2.1)
1.5*
(1.3–1.8)
1.8b,c
(1.5–2.0)
1.4*b,c
(1.1–1.6)
LDL-cholesterol (mmol/l) 2.6
(2.0–3.4)
2.9*
(2.4–3.5)
3.6e
(2.8–4.7)
3.3*e
(2.7–4.0)
4.1a,b,f
(3.4–5.1)
3.5*f
(2.7–4.1)
2.8b,c,d
(2.4–3.6)
2.9c,d
(2.2–3.5)
TG (mmol/l) 1.0
(0.9–1.3)
1.7*
(1.3–2.2)
1.8e
(1.3–2.2)
2.1*e
(1.5–2.5)
2.1a,f
(1.6–2.7)
2.3a,f
(1.8–3.0)
0.7b,c,d
(0.5–1.0)
1.1*b,c,d
(0.8–1.4)
Insulin (pmol/l) 27
(19–34)
80*
(55–104)
34
(26–50)
84*e
(63–114)
39f
(28–53)
90*f
(71–119)
24d
(17–30)
65*c,d
(41–96)
HOMA%B 123
(86–192)
288*
(200–449)
161
(113–256)
312*e
(225–523)
232a,f
(155–353)
361*f
(219–531)
90d
(63–132)
176*b,c,d
(111–239)
HOMA-IR 0.85
(0.59–1.08)
2.4*
(1.8–3.5)
1.04e
(0.77–1.49)
2.71*e
(2.00–3.91)
1.18a,f
(0.82–1.75)
2.9*f
(2.23–4.05)
0.76b,c,d
(0.50–0.97)
2.01*c,d
(1.39–3.53)
GGT (U/l) 10
(8–12)
13*
(10–17)
8
(7–9)
11*e
(8–15)
9a
(8–12)
10*f
(8–14)
12c
(10–14)
18*b,c,d
(14–24)
Alk P (U/l) 54
(45–61)
75*
(65–85)
82e
(73–93)
100*e
(81–113)
154a,f
(132–192)
150a,b
(126–181)
85b,d
(71–100)
96b,d
(79–112)
ALT (U/l) 12
(10–16)
15
(10–22)
15
(11–20)
13
(10–19)
15f,a
(11–18)
12
(9–18)
18
(13–24)
25b,c,d
(16–32)
Data presented as median (IQR)
The independent effects of lean control vs obese status and gestational age, and their interaction were examined using two-way repeated measures
ANOVA on the variables in early, mid and late gestation in pregnancy, and again in early, mid and late gestation and postpartum time points
All two-way repeated measures ANOVA analyses during pregnancy (n=111 lean, n=150 obese) and then analyses for all women attending postpartum
(n=85 lean, n=85 obese) revealed significant differences in lean vs obese status, gestational age±postpartum visit and significant interactions between
these two variables (all p<0.05). The exceptions were: fasting plasma glucose, no effect of gestation and no interaction with obese/lean status; ALT, no
effect of lean/obese status or gestational age/gestation+postpartum visit; GGT, no effect of gestation; HDL-cholesterol, insulin and HOMA%B, no
interaction with obese/lean status with gestation/+ postpartum visit (p>0.05) (data not displayed above)
Post hoc analyses for differences between lean controls vs obese at the respective time points were performed and differences denoted:
*p<0.05
Post hoc analyses for differences between time points were done separately in the controls and obese and are denoted:
a Late vs mid gestation
b Postpartum vs early gestation
c Postpartum vs mid gestation
d Postpartum vs late gestation
eMid vs early gestation
f Late vs early gestation
Alk P, alkaline phosphatase
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Part II: case–control study
Participants In case–control studies, metabolism was ex-
plored with HEC/metabolic tracer infusions and fat distribu-
tion determined with MRI/MRS studies (Table 1). Exclusions
and withdrawals were only relevant in the infusion studies at
36 weeks’ gestation where one lean and three very severely
obese women were excluded after a diagnosis of GDM, and
one lean and one very severely obese mother withdrew. In the
tracer studies, women diagnosed with GDM had data from
their 19 week clamp included in analyses. Participants in these
case–control studies were representative of those in the longi-
tudinal cohort study. Personal and anthropometric data are
shown (Tables 1 and 2).
Metabolic tracer and HEC studies The technical success of
the HECs are shown (ESM Figs 2 and 3; ESM Table 2). At
19 weeks’ gestation, basal glucose and insulin concentrations
(i.e. no insulin infusion) were greater in very severely obese vs
lean women but were comparable otherwise (ESM Table 2).
In the absence of insulin, EGP (derived from [2H2]glucose
infusion) did not change during pregnancy in either lean or
very severely obese women, and was not different in pregnan-
cy compared with non-pregnant controls (Fig. 2). During low-
dose insulin infusion, EGP was variable in non-pregnant
women, and similar between groups; in pregnancy, EGP was
suppressed in very severely obese but not lean women at 19
and 36 weeks’ gestation (Fig. 2), suggesting greater hepatic
insulin sensitivity during pregnancy in obese women. During
the high-dose HECs, insulin-stimulated glucose disposal (M/I)
showed a marked diminution from early to late pregnancy in
the lean group. Glucose disposal was lower in very severely
obese vs lean women at 19 weeks’ gestation only with similar
insulin-stimulated glucose disposal by 36 weeks’ gestation
(Fig. 2).
Lipolysis (quantified with [2H5]glycerol infusion) was sup-
pressed by insulin infusion in each of the non-pregnant and
pregnant women (Fig. 2). Lipolysis was greater in obese com-
pared with lean women at 19 weeks’ gestation in the basal
state and during the low- and high-dose HEC. At 36 weeks’
gestation there were no differences between lean and obese
groups. There were no associations between body fat distribu-
tion and glycerol turnover in early and late pregnancy and in
the non-pregnant state in lean and obese women.
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Fig. 2 Infusion studies in obese and lean control pregnant and non-preg-
nant participants. (a) EGP (mg [kgFFM]−1min−1) at baseline and low-
dose insulin infusion; (b) M/I index is the stimulated glucose disposal
rates with high-dose insulin infusion (mg [kgFFM]−1min−1 divided by
insulin concentrations at steady state [pmol/l×10]); (c) glycerol turnover
(mg [kgFFM]−1min−1) at baseline, low-dose and high-dose insulin infu-
sions. Two-way ANOVA analyses were performed on the variables to
determine the independent effects of BMI and advancing gestation/non-
pregnant state and their interaction. Obese (white bars); lean control
(black bars); *p<0.05, **p<0.01, difference in obese vs lean at 19 weeks
[w], 36 weeks and non-pregnant (NP). †p<0.05 by two-way ANOVA for
obese vs lean; ‡p<0.05 by two-way ANOVA for gestational age vs non-
pregnant status; §p<0.05 for two-way ANOVA interaction between obese
vs lean and gestational age vs non-pregnant status. See ESM Figs 2 and 3
and ESM Table 2
Diabetologia
Body fat distribution Subcutaneous abdominal, intra-
abdominal visceral, paraspinal FM depots and IMCL were
greater but there was no difference in hepatic fat at 36 weeks’
gestation in the obese vs lean women, respectively (Fig. 3).
Discussion
We hypothesised that the combination of very severe obesity and
pregnancy would lead to exaggeration of the normal, pregnancy-
related insulin resistance at all stages of pregnancy and anticipat-
ed greater circulating glucose, TG and NEFA concentrations in
these women compared with gestation-matched lean controls.
In our longitudinal cohort study, circulating glucose and
NEFA concentrations were higher in the very severely obese
women throughout pregnancy. However, fasting glucose did
not rise during pregnancy and although a rise in HOMA-IR
was seen in early- to mid-pregnancy, there was no further
increase in HOMA-IR by late pregnancy in obese women.
The difference between lean and the very severely obese
women observed in early pregnancy with respect to TG levels
was attenuated by late gestation.
This pattern was confirmed in metabolic studies using sta-
ble isotope tracers with HECs, which showed that very severe-
ly obese women are resistant to insulin-mediated stimulation
of glucose disposal and suppression of lipolysis throughout
pregnancy, but in lean women there is a progressive decline
in insulin sensitivity during pregnancy so that differences be-
tween obese and lean groups in mid-gestation were attenuated
by late pregnancy. Previous studies demonstrate the impor-
tance of TG in obese pregnant women where the failure of
insulin to suppress maternal lipolysis [19] leads to increased
circulating TG which may be hydrolysed at the placenta, lead-
ing to increased fatty acids crossing the placenta hence con-
tributing to fetal fuel excess and macrosomia [18]. In the very
severely obese women studied this appears to be attenuated by
term. Glycerol turnover was not associated with body fat dis-
tribution, in contrast to other studies which have shown sig-
nificant associations with obesity [36]. Visceral adipocytes
have greater lipolytic activity per kilogram FM, although up-
per subcutaneous adipose tissue contributes the greatest sup-
ply of NEFA [37] and differences in β-adrenoceptor density
[38] and other receptors in adipose tissue [39], and sensitivity
to hormones that regulate lipolysis [38], may be important [30,
40]. In very severe obesity, body habitus may be a less
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Fig. 3 MRI studies in obese and
lean control pregnant participants
at 36 weeks’ gestation. FM in (a)
abdominal subcutaneous depot,
(b) intra-abdominal, (c)
paraspinal, (d) hepatic fat fraction
(%) and (e) IMCL (quadriceps) as
estimated by MRI at 36 weeks’
gestation in n=10 obese
participants (white bars) and
n=10 lean controls (black bars).
For the hepatic fat fraction,
individual participants’ data
points are shown (lean, black and
white circles; obese, black
squares). Data compared between
groups using unpaired t tests or
Mann–Whitney tests as
appropriate; **p<0.01;
***p<0.001
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important factor compared with the obese state per se, al-
though as the portal circulation is not directly sampled, asso-
ciations between central obesity and glycerol turnover may be
missed [41].
The differences during insulin infusion may reflect altered
insulin sensitivity in skeletal muscle (glucose uptake) and ad-
ipose tissue (lipolysis). In the fasting low-insulin state, hepatic
insulin sensitivity is a determinant of glucose homeostasis.
Our clamp studies showed that insulin sensitivity in the liver
improved during pregnancy in the very severely obese women
but was unchanged in lean ones as reflected by the EGP.
Despite convergence in metabolism by term between the
two groups, the very severely obese pregnant women had
infants with significantly greater birthweights. Nevertheless
it may be that further increases in birthweight at late gesta-
tion—a period of time when there is accretion of FM in the
baby—are ameliorated at this important time. The complica-
tions in the very severely obese pregnant women with greater
rates of macrosomia and Caesarean section rates are in keep-
ing with other studies [5, 6]. Contrary to some studies [18], we
did not show a greater prevalence of SGA offspring from
obese mothers perhaps because these mothers had normal
glucose tolerance and were normotensive with a low preva-
lence of cigarette smoking. Glucose concentrations during
pregnancy were a predictor of adverse obstetric outcome in-
dependent from obesity as previously reported [42], but were
not associated with Caesarean section rates reflecting the im-
portance of other factors in determining Caesarean sections.
Our evidence that pregnancy has more profound metabolic
effects on lean women concord with previous human [43]
and rodent studies, where excess glucose intolerance in a
high-fat-fed group in early pregnancy was not present by late
pregnancy [44] as well as other animal studies [45].
Regarding insulin sensitivity during pregnancy, we consid-
ered whether analyses of fat depots was important in pregnan-
cy [43]. Although our obese women had greater BMI and
greater subcutaneous, visceral and paraspinal adipose depots
and skeletal muscle at the end of pregnancy, there was no
evidence of increased intrahepatic fat, agreeing with previous
human studies using ultrasound [46]. The lack of association
between intrahepatic fat with obesity in pregnancy is consis-
tent with our animal model [44]. To our knowledge, this is the
first study to quantify IMCL or intrahepatic fat in pregnancy.
Liver fat levels measuredwere lower than one would expect in
non-pregnant very severely obese women [13, 47, 48] but are
concordant with similar convergence of circulating liver
enzyme levels between the very severely obese and lean
women towards the end of pregnancy, suggesting that
pregnancy protects from liver fat accumulation and suggest a
predilection for fatty acid oxidation from intrahepatic sources
rather than from IMCL lipid, which may underpin the
improved hepatic insulin sensitivity noted above, although
confirmatory studies are required.
It may be that the hepatic fat in the very severely obese
mothers is mobilised earlier as evidenced by the GGTconcen-
trations starting to decrease in mid- as opposed to late gesta-
tion as was seen in the lean controls. Of note there was a
significant rise in ALT by late gestation in the lean mothers
only, which may reflect that gluconeogenesis [49] was upreg-
ulated in these women alone; ALT concentrations were lower
in the pregnancies complicated by severe obesity compared
with the non-pregnant state, whereas this was not the case in
the lean women. These observations are consistent with a
‘metabolic adaptation’ during pregnancy in the very severely
obese pregnant mothers and a more exaggerated response dur-
ing pregnancy in the lean mothers.
Our in-depth data in a large longitudinal study provide
insights into the metabolic changes during pregnancies com-
plicated by obesity. Importantly, these changes reflect those in
healthy obese pregnant women, and not those with GDM. In
the case–control study, we excluded data from one lean and
three obese participants after they developed GDM (according
to the strict thresholds of the IADPSG criteria, [26]). The data
from these women were still used at earlier time points. A
limitation in the longitudinal study is the decrease in numbers
followed up postpartum. However, uniquely in our study with
the aid of two representative case–control study groups that
included non-pregnant women, we have been able to under-
stand the divergent changes in insulin sensitivity in the differ-
ent body depots during pregnancy. Postpartum studies of the
hepatic fat in these women would be of particular interest.
In summary, we demonstrate that, contrary to expectations,
differences in metabolism between lean and very severely
obese mothers during pregnancy converge by the end of preg-
nancy, with a more exaggerated metabolic response to preg-
nancy in lean than very severely obese women, chiming with
the concept of ‘metabolic inflexibility’ in such obese individ-
uals [50]. However, in mid-gestation, these obese women
have substantial insulin resistance compared with lean wom-
en, which they have presumably exhibited since conception.
This suggests that, if maternal metabolic abnormalities under-
lie adverse pregnancy outcomes, then therapeutic intervention
needs to be provided early in pregnancy.
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